Clinical trials: Concentration
Disruptive Behavior Disorder
A Study of the Safety of Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
The primary purpose of this study is to document the long-term safety of an oral formulation of risperidone in the treatment of children and adolescents with conduct and other disruptive behavior disorders.
- Trial name
- NCT00236470
- Testing
- risperidone
- Volunteers
- 232 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Pain
A Study To Observe The Performance Of A Tablet Form Of PF-04531083 As Evidenced By The Concentration Of PF-04531083 In The Blood With Time Following Oral Administration To Healthy Volunteers.
A new tablet form of PF-04531083 has been manufactured. Previously the compound was administered as a solution/suspension to healthy volunteers.
- Trial name
- NCT01119235
- Testing
- PF-04531083
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Psoriasis
A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test
The purpose of this study is to investigate dose-response relationship, antipsoriatic efficacy and safety of different concentrations of topical formulations with AN2728 in subjects with psoriasis vulgaris.
- Trial name
- NCT00763204
- Testing
- AN2728 Cream, 2%, AN2728 Cream, 1%, AN2728 Cream, 0.3%
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder
Attentin® in Children and Adolescents With ADHD - A Non-interventional Study
The practicality of most ADHD medications is not or only moderately examined under long term routine conditions. Therefore, in this multi-centre, multi-national prospective non-interventional study, a recommended follow-up time…
- Trial name
- Attention (NCT02801604)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
ADHD
Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)
The goal of this clinical trial is to evaluate the efficacy and safety of NRCT-101SR compared to placebo in adult patients with ADHD aged 18 years and older.
- Trial name
- NCT05683249
- Testing
- NRCT-101-SR
- Where
- 9 sites in United States
- Volunteers
- 223 people
- Sponsor
- Neurocentria, Inc.
Healthy Volunteer
A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)
This study will assess the bioequivalence in healthy participants between a high-concentration formulation of lebrikizumab withdrawn from a vial and administered SC as a single injection by a needle and syringe, and a…
- Trial name
- NCT02486809
- Testing
- Lebrikizumab
- Where
- 4 sites in United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
This study is a multi-center, randomized, double-blind, placebo-controlled, phase 3 study of MDX (1400 mg daily) for 10 weeks compared with placebo in adults with ADHD.
- Trial name
- NCT02477748
- Testing
- MDX
- Where
- 38 sites in United States, Israel
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- Alcobra Ltd.
Kidney Failure
Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients
The purpose of this study is to determine the quantity of iron derived from SFP that is transferred from the dialysate to patients during a single dialysis session.
- Trial name
- NCT01894906
- Testing
- Soluble Ferric Pyrophosphate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Healthy
A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers
This study is designed to evaluate the safety and plasma concentrations of PF-06649751 in healthy volunteers following one or two times daily oral dosing of PF-06649751 for 14 days (Cohorts 1 - 4), 21 days (Cohort 5), or 28 days…
- Trial name
- NCT02066909
- Testing
- 0.15 mg PF-06649751, 0.5 mg PF-06649751, 1.5 mg PF-06649751
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Pfizer
Acne Vulgaris
A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne
This is a 12 week clinical trial in subjects with acne vulgaris. Subjects will be randomized to NVN1000 1% Gel, NVN1000 4% Gel or Vehicle Gel twice daily.
- Trial name
- NCT01844752
- Testing
- NVN1000 1% Gel, NVN1000 4% Gel, Vehicle Gel
- Where
- 3 sites in Dominican Republic, Honduras and 1 more
- Volunteers
- 153 people
- Sponsor
- Novan, Inc.
Muscular Dystrophies
A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling
This is a Phase I, open-label, single-dose, 1-period study to compare EDG-5506 concentrations measured from venous and capillary blood sampling in healthy adult subjects.
- Trial name
- NCT05492734
- Testing
- EDG-5506
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Edgewise Therapeutics, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Drug Use Study With Intuniv® in Australia
This study will evaluate and analyze prescribing behaviors of physicians and determine whether Intuniv was correctly prescribed in Australia.
- Trial name
- NCT04866030
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- Shire
Healthy
Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults
This study is designed to look at the potential for an investigational drug (PF-04995274, under development by Pfizer, Inc. as a potential treatment for Alzheimer's disease) to reverse changes in memory and learning/problem…
- Trial name
- NCT01345864
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Pfizer
ADHD
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
- Trial name
- NCT03618030
- Testing
- PRC-063 oral capsules
- Where
- 8 sites in United States
- Volunteers
- 288 people
- Sponsor
- Purdue Pharma, Canada
Attention Deficit Hyperactivity Disorder (ADHD)
A Long-term Trial of EB-1020 in Adult Patients With ADHD
The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan
- Trial name
- NCT06926829
- Testing
- EB-1020 (Centanafadine) 164.4 mg, EB-1020 (Centanafadine) 328.8 mg
- Where
- Japan
- Volunteers
- 180 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Cicatrix, Re-epithelialisation
Investigation Into the Safety of Intradermal Juvidex (M6P) Administered to Wounds of Healthy Subjects
The purpose of this study was to investigate the safety and toleration of various doses of intradermal Juvidex (mannose-6-phosphate) administered to punch biopsies of normal subjects.
- Trial name
- NCT00984854
- Testing
- Juvidex
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Renovo
To Determine Brain Target Occupancy of BPN14770
A Phase 1, Open-Label, PET Study of T2310 & BPN14770
This is a sponsor initiated, single site, first-in-human study of an investigational imaging agent for quantifying the topographically specific concentrations of the phosphodiesterase enzyme Type 4D (PDE4D) with positron emission…
- Trial name
- NCT04044781
- Testing
- BPN14770, T2310
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Tetra Discovery Partners
Renal Impairment
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.
The purpose of this parallel group, Phase 1, open-label, 2-arm study is to assess the effect of severe (Part A) and moderate (Part B, conditional) renal impairment (RI) on pharmacokinetics (PK), safety and tolerability of…
- Trial name
- NCT05282030
- Testing
- tolebrutinib
- Where
- 4 sites in United States, Germany
- Volunteers
- 22 people
- Sponsor
- Sanofi
Smoking
Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Electronic Cigarettes vs Combustible Cigarettes and Nicotine Gum
The purpose of this study is to measure plasma nicotine uptake parameters, physiological measures, and subjective effect measures in smokers during and following a single ad libitum use of three electronic cigarettes versus…
- Trial name
- NCT02269514
- Testing
- Own Brand Cigarette, Electronic Cigarette #1, Electronic Cigarette #2
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- R.J. Reynolds Vapor Company
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT03605849
- Testing
- Centanafadine SR
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.